Clinical features and treatment outcomes of langerhans cell histiocytosis

A nationwide survey from Korea histiocytosis working party

Bo Eun Kim, Kyung Nam Koh, Jin Kyung Suh, Ho Joon Im, Joon Sup Song, Ji Won Lee, Hyoung Jin Kang, Kyung Duck Park, Hee Young Shin, Hyoung Soo Choi, Soo Hyun Lee, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Hye Lim Jung, Nak Gyun Chung, Bin Cho, Hack Ki Kim, Chuhl Joo Lyu, Hee Jo Baek & 22 others Hoon Kook, Jun Eun Park, Hyeon Jin Park, Byung Kiu Park, Eun Sun Yoo, Kyung Ha Ryu, Kun Soo Lee, Heung Sik Kim, Jae Min Lee, Eun Sil Park, Hoi Soo Yoon, Kwang Chul Lee, Mee Jeong Lee, Young Tak Lim, Hwang Min Kim, Sang Kyu Park, Jeong A. Park, Soon Ki Kim, Meerim Park, Yeon Jung Lim, Young Ho Lee, Jong Jin Seo

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

A nationwide survey was conducted to clarify the clinical features and outcomes of Korean children with Langerhans cell histiocytosis (LCH). Korea Histiocytosis Working Party analyzed the data of 603 patients who were diagnosed with LCH between 1986 and 2010 from 28 institutions in Korea. Median age at diagnosis was 65 months (range, 0 to 276 mo). Bone was the most frequently affected organ (79.6%) followed by skin (19.2%). Initially, 419 patients (69.5%) had single-system involvement (SS), 85 (14.1%) with multisystem (MS) disease without risk organ involvement (MS-RO), and 99 (16.4%) multisystem disease with risk organ involvement (MS-RO). The 5-year overall survival (OS) rates in the SS, MS-RO, and MS-RO groups were 99.8%, 98.4%, and 77.0%, respectively (P<0.001), and the 5-year reactivation rates were 17.9%, 33.5%, and 34.3%, respectively (P<0.001). The OS rate was lower in patients with RO involvement (P=0.025) and lack of response to initial treatment (P=0.001). MS involvement (P=0.036) was an independent risk factor for reactivation. Permanent consequences were documented in 99 patients (16.4%). Reactivation of disease, MS involvement, and age at diagnosis ≤2 years were associated with higher incidence of permanent consequences. This study emphasized that further efforts are required to improve survival of MS-RO patients and reduce reactivation in younger patients with MS involvement.

Original languageEnglish
Pages (from-to)125-133
Number of pages9
JournalJournal of Pediatric Hematology/Oncology
Volume36
Issue number2
DOIs
Publication statusPublished - 2014 Mar 1

Fingerprint

Histiocytosis
Langerhans Cell Histiocytosis
Korea
Survival Rate
Surveys and Questionnaires
Bone and Bones
Skin
Survival
Incidence

Keywords

  • Langerhans cell histiocytosis
  • outcome
  • permanent consequence
  • reactivation

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Clinical features and treatment outcomes of langerhans cell histiocytosis : A nationwide survey from Korea histiocytosis working party. / Kim, Bo Eun; Koh, Kyung Nam; Suh, Jin Kyung; Im, Ho Joon; Song, Joon Sup; Lee, Ji Won; Kang, Hyoung Jin; Park, Kyung Duck; Shin, Hee Young; Choi, Hyoung Soo; Lee, Soo Hyun; Yoo, Keon Hee; Sung, Ki Woong; Koo, Hong Hoe; Jung, Hye Lim; Chung, Nak Gyun; Cho, Bin; Kim, Hack Ki; Lyu, Chuhl Joo; Baek, Hee Jo; Kook, Hoon; Park, Jun Eun; Park, Hyeon Jin; Park, Byung Kiu; Yoo, Eun Sun; Ryu, Kyung Ha; Lee, Kun Soo; Kim, Heung Sik; Lee, Jae Min; Park, Eun Sil; Yoon, Hoi Soo; Lee, Kwang Chul; Lee, Mee Jeong; Lim, Young Tak; Kim, Hwang Min; Park, Sang Kyu; Park, Jeong A.; Kim, Soon Ki; Park, Meerim; Lim, Yeon Jung; Lee, Young Ho; Seo, Jong Jin.

In: Journal of Pediatric Hematology/Oncology, Vol. 36, No. 2, 01.03.2014, p. 125-133.

Research output: Contribution to journalArticle

Kim, BE, Koh, KN, Suh, JK, Im, HJ, Song, JS, Lee, JW, Kang, HJ, Park, KD, Shin, HY, Choi, HS, Lee, SH, Yoo, KH, Sung, KW, Koo, HH, Jung, HL, Chung, NG, Cho, B, Kim, HK, Lyu, CJ, Baek, HJ, Kook, H, Park, JE, Park, HJ, Park, BK, Yoo, ES, Ryu, KH, Lee, KS, Kim, HS, Lee, JM, Park, ES, Yoon, HS, Lee, KC, Lee, MJ, Lim, YT, Kim, HM, Park, SK, Park, JA, Kim, SK, Park, M, Lim, YJ, Lee, YH & Seo, JJ 2014, 'Clinical features and treatment outcomes of langerhans cell histiocytosis: A nationwide survey from Korea histiocytosis working party', Journal of Pediatric Hematology/Oncology, vol. 36, no. 2, pp. 125-133. https://doi.org/10.1097/MPH.0000000000000054
Kim, Bo Eun ; Koh, Kyung Nam ; Suh, Jin Kyung ; Im, Ho Joon ; Song, Joon Sup ; Lee, Ji Won ; Kang, Hyoung Jin ; Park, Kyung Duck ; Shin, Hee Young ; Choi, Hyoung Soo ; Lee, Soo Hyun ; Yoo, Keon Hee ; Sung, Ki Woong ; Koo, Hong Hoe ; Jung, Hye Lim ; Chung, Nak Gyun ; Cho, Bin ; Kim, Hack Ki ; Lyu, Chuhl Joo ; Baek, Hee Jo ; Kook, Hoon ; Park, Jun Eun ; Park, Hyeon Jin ; Park, Byung Kiu ; Yoo, Eun Sun ; Ryu, Kyung Ha ; Lee, Kun Soo ; Kim, Heung Sik ; Lee, Jae Min ; Park, Eun Sil ; Yoon, Hoi Soo ; Lee, Kwang Chul ; Lee, Mee Jeong ; Lim, Young Tak ; Kim, Hwang Min ; Park, Sang Kyu ; Park, Jeong A. ; Kim, Soon Ki ; Park, Meerim ; Lim, Yeon Jung ; Lee, Young Ho ; Seo, Jong Jin. / Clinical features and treatment outcomes of langerhans cell histiocytosis : A nationwide survey from Korea histiocytosis working party. In: Journal of Pediatric Hematology/Oncology. 2014 ; Vol. 36, No. 2. pp. 125-133.
@article{d1580b9920c7461b87b6c9de618157c4,
title = "Clinical features and treatment outcomes of langerhans cell histiocytosis: A nationwide survey from Korea histiocytosis working party",
abstract = "A nationwide survey was conducted to clarify the clinical features and outcomes of Korean children with Langerhans cell histiocytosis (LCH). Korea Histiocytosis Working Party analyzed the data of 603 patients who were diagnosed with LCH between 1986 and 2010 from 28 institutions in Korea. Median age at diagnosis was 65 months (range, 0 to 276 mo). Bone was the most frequently affected organ (79.6{\%}) followed by skin (19.2{\%}). Initially, 419 patients (69.5{\%}) had single-system involvement (SS), 85 (14.1{\%}) with multisystem (MS) disease without risk organ involvement (MS-RO), and 99 (16.4{\%}) multisystem disease with risk organ involvement (MS-RO). The 5-year overall survival (OS) rates in the SS, MS-RO, and MS-RO groups were 99.8{\%}, 98.4{\%}, and 77.0{\%}, respectively (P<0.001), and the 5-year reactivation rates were 17.9{\%}, 33.5{\%}, and 34.3{\%}, respectively (P<0.001). The OS rate was lower in patients with RO involvement (P=0.025) and lack of response to initial treatment (P=0.001). MS involvement (P=0.036) was an independent risk factor for reactivation. Permanent consequences were documented in 99 patients (16.4{\%}). Reactivation of disease, MS involvement, and age at diagnosis ≤2 years were associated with higher incidence of permanent consequences. This study emphasized that further efforts are required to improve survival of MS-RO patients and reduce reactivation in younger patients with MS involvement.",
keywords = "Langerhans cell histiocytosis, outcome, permanent consequence, reactivation",
author = "Kim, {Bo Eun} and Koh, {Kyung Nam} and Suh, {Jin Kyung} and Im, {Ho Joon} and Song, {Joon Sup} and Lee, {Ji Won} and Kang, {Hyoung Jin} and Park, {Kyung Duck} and Shin, {Hee Young} and Choi, {Hyoung Soo} and Lee, {Soo Hyun} and Yoo, {Keon Hee} and Sung, {Ki Woong} and Koo, {Hong Hoe} and Jung, {Hye Lim} and Chung, {Nak Gyun} and Bin Cho and Kim, {Hack Ki} and Lyu, {Chuhl Joo} and Baek, {Hee Jo} and Hoon Kook and Park, {Jun Eun} and Park, {Hyeon Jin} and Park, {Byung Kiu} and Yoo, {Eun Sun} and Ryu, {Kyung Ha} and Lee, {Kun Soo} and Kim, {Heung Sik} and Lee, {Jae Min} and Park, {Eun Sil} and Yoon, {Hoi Soo} and Lee, {Kwang Chul} and Lee, {Mee Jeong} and Lim, {Young Tak} and Kim, {Hwang Min} and Park, {Sang Kyu} and Park, {Jeong A.} and Kim, {Soon Ki} and Meerim Park and Lim, {Yeon Jung} and Lee, {Young Ho} and Seo, {Jong Jin}",
year = "2014",
month = "3",
day = "1",
doi = "10.1097/MPH.0000000000000054",
language = "English",
volume = "36",
pages = "125--133",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Clinical features and treatment outcomes of langerhans cell histiocytosis

T2 - A nationwide survey from Korea histiocytosis working party

AU - Kim, Bo Eun

AU - Koh, Kyung Nam

AU - Suh, Jin Kyung

AU - Im, Ho Joon

AU - Song, Joon Sup

AU - Lee, Ji Won

AU - Kang, Hyoung Jin

AU - Park, Kyung Duck

AU - Shin, Hee Young

AU - Choi, Hyoung Soo

AU - Lee, Soo Hyun

AU - Yoo, Keon Hee

AU - Sung, Ki Woong

AU - Koo, Hong Hoe

AU - Jung, Hye Lim

AU - Chung, Nak Gyun

AU - Cho, Bin

AU - Kim, Hack Ki

AU - Lyu, Chuhl Joo

AU - Baek, Hee Jo

AU - Kook, Hoon

AU - Park, Jun Eun

AU - Park, Hyeon Jin

AU - Park, Byung Kiu

AU - Yoo, Eun Sun

AU - Ryu, Kyung Ha

AU - Lee, Kun Soo

AU - Kim, Heung Sik

AU - Lee, Jae Min

AU - Park, Eun Sil

AU - Yoon, Hoi Soo

AU - Lee, Kwang Chul

AU - Lee, Mee Jeong

AU - Lim, Young Tak

AU - Kim, Hwang Min

AU - Park, Sang Kyu

AU - Park, Jeong A.

AU - Kim, Soon Ki

AU - Park, Meerim

AU - Lim, Yeon Jung

AU - Lee, Young Ho

AU - Seo, Jong Jin

PY - 2014/3/1

Y1 - 2014/3/1

N2 - A nationwide survey was conducted to clarify the clinical features and outcomes of Korean children with Langerhans cell histiocytosis (LCH). Korea Histiocytosis Working Party analyzed the data of 603 patients who were diagnosed with LCH between 1986 and 2010 from 28 institutions in Korea. Median age at diagnosis was 65 months (range, 0 to 276 mo). Bone was the most frequently affected organ (79.6%) followed by skin (19.2%). Initially, 419 patients (69.5%) had single-system involvement (SS), 85 (14.1%) with multisystem (MS) disease without risk organ involvement (MS-RO), and 99 (16.4%) multisystem disease with risk organ involvement (MS-RO). The 5-year overall survival (OS) rates in the SS, MS-RO, and MS-RO groups were 99.8%, 98.4%, and 77.0%, respectively (P<0.001), and the 5-year reactivation rates were 17.9%, 33.5%, and 34.3%, respectively (P<0.001). The OS rate was lower in patients with RO involvement (P=0.025) and lack of response to initial treatment (P=0.001). MS involvement (P=0.036) was an independent risk factor for reactivation. Permanent consequences were documented in 99 patients (16.4%). Reactivation of disease, MS involvement, and age at diagnosis ≤2 years were associated with higher incidence of permanent consequences. This study emphasized that further efforts are required to improve survival of MS-RO patients and reduce reactivation in younger patients with MS involvement.

AB - A nationwide survey was conducted to clarify the clinical features and outcomes of Korean children with Langerhans cell histiocytosis (LCH). Korea Histiocytosis Working Party analyzed the data of 603 patients who were diagnosed with LCH between 1986 and 2010 from 28 institutions in Korea. Median age at diagnosis was 65 months (range, 0 to 276 mo). Bone was the most frequently affected organ (79.6%) followed by skin (19.2%). Initially, 419 patients (69.5%) had single-system involvement (SS), 85 (14.1%) with multisystem (MS) disease without risk organ involvement (MS-RO), and 99 (16.4%) multisystem disease with risk organ involvement (MS-RO). The 5-year overall survival (OS) rates in the SS, MS-RO, and MS-RO groups were 99.8%, 98.4%, and 77.0%, respectively (P<0.001), and the 5-year reactivation rates were 17.9%, 33.5%, and 34.3%, respectively (P<0.001). The OS rate was lower in patients with RO involvement (P=0.025) and lack of response to initial treatment (P=0.001). MS involvement (P=0.036) was an independent risk factor for reactivation. Permanent consequences were documented in 99 patients (16.4%). Reactivation of disease, MS involvement, and age at diagnosis ≤2 years were associated with higher incidence of permanent consequences. This study emphasized that further efforts are required to improve survival of MS-RO patients and reduce reactivation in younger patients with MS involvement.

KW - Langerhans cell histiocytosis

KW - outcome

KW - permanent consequence

KW - reactivation

UR - http://www.scopus.com/inward/record.url?scp=84896706709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896706709&partnerID=8YFLogxK

U2 - 10.1097/MPH.0000000000000054

DO - 10.1097/MPH.0000000000000054

M3 - Article

VL - 36

SP - 125

EP - 133

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 2

ER -